Last10K.com

Canfite Biopharma Ltd. (CANF) SEC Filing 6-K Foreign Issuer report for the period ending Thursday, October 25, 2018

Canfite Biopharma Ltd.

CIK: 1536196 Ticker: CANF

View differences made from one to another to evaluate Canfite Biopharma Ltd.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Canfite Biopharma Ltd..

Continue

Assess how Canfite Biopharma Ltd.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Canfite Biopharma Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Canfite Biopharma Ltd. provided additional information to their SEC Filing as exhibits

Ticker: CANF
CIK: 1536196
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001213900-18-014437
Submitted to the SEC: Thu Oct 25 2018 7:11:09 AM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Thursday, October 25, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/canf/0001213900-18-014437.htm